董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward B. Smith, III | 男 | Director | 46 | 11.94万美元 | 未持股 | 2021-08-03 |
| John K.A. Prendergast | 男 | Lead Director | 67 | 40.50万美元 | 未持股 | 2021-08-03 |
| Jeffrey Wolf | 男 | Chairman of the Board, Chief Executive Officer and President | 58 | 641.99万美元 | 未持股 | 2021-08-03 |
| John Monahan | 男 | Director | 74 | 10.84万美元 | 未持股 | 2021-08-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William L. Ostrander | 男 | Chief Financial Officer, Controller and Secretary | 53 | 33.83万美元 | 未持股 | 2021-08-03 |
| Jeffrey Wolf | 男 | Chairman of the Board, Chief Executive Officer and President | 58 | 641.99万美元 | 未持股 | 2021-08-03 |
董事简历
中英对照 | 中文 | 英文- Edward B. Smith, III
-
EdwardB.Smith，III自2010年11月以来一直在我们的董事会任职。自2015年1月1日起，Smith先生还一直担任Aristar Capital Management，LLC（一家总部位于纽约的投资公司，成立于2015年）的管理成员。2017年4月14日至2017年7月14日，史密斯先生担任Agritech Worldwide，Inc.（前身为Z Trim Holdings，Inc.（OTCPink:FBER））的临时首席执行官兼临时首席财务官，该公司是一家环保型农业功能成分制造商。2015年1月至2016年5月，Smith先生还担任Agritech的首席执行官，并于2009年至2017年7月担任Agritech的董事会成员。从2005年4月到2014年12月，Smith先生担任Brightline Capital Management，LLC（“；BCM”；）的管理合伙人，这是一家总部位于纽约的投资公司，成立于2005年。创立BCM之前，Smith从2004年到2005年在Gracie Capital任职，从1999年到2001年在GTCR Golder Rauner任职，从1997年到1999年在Credit Suisse First Boston任职。Smith先生持有Harvard College社会研究文学学士学位和Harvard Business School工商管理硕士学位。
Edward B. Smith, III has served on our Board of Directors since November 2010. Since January 1 2015 Mr. Smith has also been Managing Member of Aristar Capital Management, LLC, a New York-based investment firm founded in 2015. From April 14 2017 through July 14 2017 Mr. Smith served as the interim Chief Executive Officer and interim Chief Financial Officer of Agritech Worldwide, Inc. “Agritech,” formerly Z Trim Holdings, Inc., a manufacturer of environmentally friendly agricultural functional ingredients, From January 2015 until May 2016 Mr. Smith also served as the Chief Executive Officer of Agritech and from 2009 through July 2017 he served as a board member of Agritech. From April 2005 through December 2014 Mr. Smith served as the Managing Partner of Brightline Capital Management, LLC (“BCM”), a New York-based investment firm founded in 2005. Prior to founding BCM, Mr. Smith worked at Gracie Capital from 2004 to 2005 GTCR Golder Rauner from 1999 to2001 and Credit Suisse First Boston from 1997 to1999. Mr. Smith holds a Bachelor of Arts in Social Studies from Harvard College and a Masters in Business Administration from Harvard Business School. - EdwardB.Smith，III自2010年11月以来一直在我们的董事会任职。自2015年1月1日起，Smith先生还一直担任Aristar Capital Management，LLC（一家总部位于纽约的投资公司，成立于2015年）的管理成员。2017年4月14日至2017年7月14日，史密斯先生担任Agritech Worldwide，Inc.（前身为Z Trim Holdings，Inc.（OTCPink:FBER））的临时首席执行官兼临时首席财务官，该公司是一家环保型农业功能成分制造商。2015年1月至2016年5月，Smith先生还担任Agritech的首席执行官，并于2009年至2017年7月担任Agritech的董事会成员。从2005年4月到2014年12月，Smith先生担任Brightline Capital Management，LLC（“；BCM”；）的管理合伙人，这是一家总部位于纽约的投资公司，成立于2005年。创立BCM之前，Smith从2004年到2005年在Gracie Capital任职，从1999年到2001年在GTCR Golder Rauner任职，从1997年到1999年在Credit Suisse First Boston任职。Smith先生持有Harvard College社会研究文学学士学位和Harvard Business School工商管理硕士学位。
- Edward B. Smith, III has served on our Board of Directors since November 2010. Since January 1 2015 Mr. Smith has also been Managing Member of Aristar Capital Management, LLC, a New York-based investment firm founded in 2015. From April 14 2017 through July 14 2017 Mr. Smith served as the interim Chief Executive Officer and interim Chief Financial Officer of Agritech Worldwide, Inc. “Agritech,” formerly Z Trim Holdings, Inc., a manufacturer of environmentally friendly agricultural functional ingredients, From January 2015 until May 2016 Mr. Smith also served as the Chief Executive Officer of Agritech and from 2009 through July 2017 he served as a board member of Agritech. From April 2005 through December 2014 Mr. Smith served as the Managing Partner of Brightline Capital Management, LLC (“BCM”), a New York-based investment firm founded in 2005. Prior to founding BCM, Mr. Smith worked at Gracie Capital from 2004 to 2005 GTCR Golder Rauner from 1999 to2001 and Credit Suisse First Boston from 1997 to1999. Mr. Smith holds a Bachelor of Arts in Social Studies from Harvard College and a Masters in Business Administration from Harvard Business School.
- John K.A. Prendergast
-
John K.A. Prendergast，是Palatin的共同创始人；2000年6月14日起，担任董事长；1996年8月起，担任董事。他从1993年起，就是Summercloud Bay的总裁、唯一股东，这是服务于生物技术行业的独立咨询公司。他现为Antyra的董事、执行董事长，这是私营的生物制药公司。之前，他曾担任一些生物生命科学公司的董事：AVAX Technologies, Inc.、Avigen, Inc. 和 MediciNova, Inc.1991年10月至1997年12月，他是The Castle Group的总经理，这是一个医疗行业风投公司。他获得了的澳大利亚悉尼University of New South Wales的硕士、博士学位，以及Harvard University的管理学C.S.S。
John K.A. Prendergast has served on our Board since April 2016. Dr. Prendergast is co-founder of Palatin Technologies, Inc. "Palatin", a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential (NYSE MKT: PTN). Dr. Prendergast has been Chairman of the Board of Palatin since June 14 2000 and a director since August 1996. Dr. Prendergast has been president and sole stockholder of Summercloud Bay, Inc., an independent consulting firm providing services to the biotechnology industry, since 1993. Dr. Prendergast is a director and executive chairman of the board of directors of Antyra, Inc., a privately-held biopharmaceutical firm. He was previously a member of the board of the life science companies AVAX Technologies, Inc., Avigen, Inc. and MediciNova, Inc. From October 1991 through December 1997 Dr. Prendergast was a managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University. - John K.A. Prendergast，是Palatin的共同创始人；2000年6月14日起，担任董事长；1996年8月起，担任董事。他从1993年起，就是Summercloud Bay的总裁、唯一股东，这是服务于生物技术行业的独立咨询公司。他现为Antyra的董事、执行董事长，这是私营的生物制药公司。之前，他曾担任一些生物生命科学公司的董事：AVAX Technologies, Inc.、Avigen, Inc. 和 MediciNova, Inc.1991年10月至1997年12月，他是The Castle Group的总经理，这是一个医疗行业风投公司。他获得了的澳大利亚悉尼University of New South Wales的硕士、博士学位，以及Harvard University的管理学C.S.S。
- John K.A. Prendergast has served on our Board since April 2016. Dr. Prendergast is co-founder of Palatin Technologies, Inc. "Palatin", a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential (NYSE MKT: PTN). Dr. Prendergast has been Chairman of the Board of Palatin since June 14 2000 and a director since August 1996. Dr. Prendergast has been president and sole stockholder of Summercloud Bay, Inc., an independent consulting firm providing services to the biotechnology industry, since 1993. Dr. Prendergast is a director and executive chairman of the board of directors of Antyra, Inc., a privately-held biopharmaceutical firm. He was previously a member of the board of the life science companies AVAX Technologies, Inc., Avigen, Inc. and MediciNova, Inc. From October 1991 through December 1997 Dr. Prendergast was a managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University.
- Jeffrey Wolf
-
Jeffrey Wolf，一名法学博士，自2006年以来成为董事，在基于研究和技术进行创建、融资、培育和发展新企业方面拥有大量经验。在2008年8月，他创立Heat Biologics, Inc.（纳斯达克交易代码：HTBX），这是一家上市公司，从事对抗癌症和其他疾病的药物研究与开发。自2010年4月以来，他担任Heat Biologics, Inc.的首席执行官和董事会主席。在成立Heat Biologics, Inc.之前，从1997年6月至2011年3月，他担任Seed-One Ventures, LLC的常务董事，这是一家风险投资公司，专注于刚成立的特殊医疗公司的创设和成长。自Seed-One成立以来，他创办并运行一些医疗公司。他新创的企业包括Avigen（一家位于旧金山的基因治疗公司），他担任其联合创始人和董事；TyRx Pharma（一家位于普林斯顿的公司，专注于生物相容性聚合物的发展），他担任其联合创始人兼董事长；EluSys Therapeutics（一家位于新泽西（New Jersey）的公司，专注于将血源性病原体移除的新技术的发展），他担任其联合创始人、董事长兼首席执行官；以及GenerationOne（一家位于迈阿密（Miami）的公司，专注于移动协同式医疗（mobile-based collaborative care）），他担任其创始人、董事长兼首席执行官。他从斯坦福商学院（Stanford Business School）获得M.B.A。学位；从纽约大学法学院（New York University School of Law）获得法学博士学位；从芝加哥大学（University of Chicago）获得学士学位，在那里他以优异的成绩从经济学专业毕业。他是几个Seed-One投资组合公司的董事。
Jeffrey Wolf,who has been a member of the Company’s Board of Directors since 2006 has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In August 2008 Mr. Wolf founded Heat Biologics, Inc. NASDAQ: HTBX, a publicly traded company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010 Mr. Wolf has served as the Chief Executive Officer and Chairman of the Board of Heat Biologics, Inc. Prior to founding Heat Biologics, Inc., from June 1997 to March 2011 Mr. Wolf has served as managing director at Seed-One Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding Seed-One, Mr. Wolf has founded and run several medical companies. Mr. Wolf’s start-ups include Avigen, a San Francisco-based gene therapy company where he was a co-founder and director; TyRx Pharma, a Princeton-based company focused on the development of bio-compatible polymers where he was a co-founder and Chairman; EluSys Therapeutics, a New Jersey company focused on the development of novel technology to remove blood-borne pathogens where he was a cofounder, Chairman and Chief Executive Officer; and GenerationOne, a Miami-based company focused on mobile-based collaborative care, where he was the founder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as a director of several Seed-One portfolio companies. - Jeffrey Wolf，一名法学博士，自2006年以来成为董事，在基于研究和技术进行创建、融资、培育和发展新企业方面拥有大量经验。在2008年8月，他创立Heat Biologics, Inc.（纳斯达克交易代码：HTBX），这是一家上市公司，从事对抗癌症和其他疾病的药物研究与开发。自2010年4月以来，他担任Heat Biologics, Inc.的首席执行官和董事会主席。在成立Heat Biologics, Inc.之前，从1997年6月至2011年3月，他担任Seed-One Ventures, LLC的常务董事，这是一家风险投资公司，专注于刚成立的特殊医疗公司的创设和成长。自Seed-One成立以来，他创办并运行一些医疗公司。他新创的企业包括Avigen（一家位于旧金山的基因治疗公司），他担任其联合创始人和董事；TyRx Pharma（一家位于普林斯顿的公司，专注于生物相容性聚合物的发展），他担任其联合创始人兼董事长；EluSys Therapeutics（一家位于新泽西（New Jersey）的公司，专注于将血源性病原体移除的新技术的发展），他担任其联合创始人、董事长兼首席执行官；以及GenerationOne（一家位于迈阿密（Miami）的公司，专注于移动协同式医疗（mobile-based collaborative care）），他担任其创始人、董事长兼首席执行官。他从斯坦福商学院（Stanford Business School）获得M.B.A。学位；从纽约大学法学院（New York University School of Law）获得法学博士学位；从芝加哥大学（University of Chicago）获得学士学位，在那里他以优异的成绩从经济学专业毕业。他是几个Seed-One投资组合公司的董事。
- Jeffrey Wolf,who has been a member of the Company’s Board of Directors since 2006 has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In August 2008 Mr. Wolf founded Heat Biologics, Inc. NASDAQ: HTBX, a publicly traded company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010 Mr. Wolf has served as the Chief Executive Officer and Chairman of the Board of Heat Biologics, Inc. Prior to founding Heat Biologics, Inc., from June 1997 to March 2011 Mr. Wolf has served as managing director at Seed-One Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding Seed-One, Mr. Wolf has founded and run several medical companies. Mr. Wolf’s start-ups include Avigen, a San Francisco-based gene therapy company where he was a co-founder and director; TyRx Pharma, a Princeton-based company focused on the development of bio-compatible polymers where he was a co-founder and Chairman; EluSys Therapeutics, a New Jersey company focused on the development of novel technology to remove blood-borne pathogens where he was a cofounder, Chairman and Chief Executive Officer; and GenerationOne, a Miami-based company focused on mobile-based collaborative care, where he was the founder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as a director of several Seed-One portfolio companies.
- John Monahan
-
John Monahan目前担任Synthetic Biologics, Inc.的首席技术官，该公司是一家关注于合成DNA疗法和治疗严重疾病的创新性药物开发的生物技术公司。Monahan先生在1992年联合创建了Avigen Inc.（纳斯达克（NASDAQ）代码：AVGN），该公司随后由于开发治疗严重人类疾病的新型药物为成为行业龙头。在Avigen公司担任首席执行官的12年中他在一些私人和公共融资中，共筹得超过2亿3500万美元，包括首次公开募股。从1989年到1992年，他是位于加州阿拉米达的Somatix Therapy Corp.研发部门的副总裁，同时从1985年到1989年是位于加州阿拉米达的Triton Biosciences Inc.所属分子和细胞生物部门的董事。此前，从1982年到1985年，他是位于新泽西州纳特利的Hoffmann-LaRoche, Inc.分子遗传部门的研究团队主管，同时从1975年到1977年，他是特州休斯敦市贝勒医学院（Baylor College of Medicine）讲师。他在1974年从加拿大的麦克马斯特大学（McMaster University）获得生物化学博士学位，在1969年从爱尔兰都柏林大学（University College Dublin）获得学士学位。Monahan先生是加州Tacere Therapeutics董事会成员。他还是一些爱尔兰生物技术公司的董事会成员，包括Genable、Cellix、Luxcel、Identigen、Pharmatrin以及GK Technologies。
John Monahan has been a member of the Company’s Board of Directors since November 11 2020. Dr. Monahan has served on the board of directors of Heat Biologics, Inc. Nasdaq: HTBX, a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines since November 2009 and from August 2016 until May 2021 also served on the board of directors of the biotech company Anixa Biosciences, Inc. (formerly known as ITUS Corporation)(Nasdaq: ANIX), a biotechnology company focused on using the body’s immune system to diagnose, treat and prevent cancer. He is also a board member of Cellix Ltd. (Ireland) and has served on a number of other public and private boards over the years. Dr. Monahan Co-Founded Avigen Inc. (Nasdaq: AVGN) in 1992 a company which has become a leader in its sector for the development of novel pharmaceutical products for the treatment of serious human diseases. Over a 12 year period as Chief Executive Officer of Avigen he raised over $235 million in several private and public financings including its initial public offering. From 1989-1992 he was Vice President of Research & Development at Somatix Therapy Corp., Alameda, CA and from 1985-1989 he was Director of Molecular & Cell Biology at Triton Biosciences Inc., Alameda, CA. Prior to that from 1982-1985 he was Research Group Chief, Department of Molecular Genetics, Hoffmann-LaRoche, Inc. Nutley, NJ, and from 1975 to 1977 he was an Instructor at Baylor College of Medicine, Houston TX. Dr. Monahan served as a scientific advisory consultant to the Company from 2015 to November 10 2020 and from 2010 through 2015 he was the Company’s Senior Executive Vice President of Research & Development. Dr. Monahan was also a Scientific Advisory Board member of Agilis Biotherapeutics (recently merged into PTC Therapeutics), from 2014 to 2019. Dr. Monahan received his Ph.D. in Biochemistry from McMaster University, Canada and his B.Sc. from University College Dublin, Ireland. - John Monahan目前担任Synthetic Biologics, Inc.的首席技术官，该公司是一家关注于合成DNA疗法和治疗严重疾病的创新性药物开发的生物技术公司。Monahan先生在1992年联合创建了Avigen Inc.（纳斯达克（NASDAQ）代码：AVGN），该公司随后由于开发治疗严重人类疾病的新型药物为成为行业龙头。在Avigen公司担任首席执行官的12年中他在一些私人和公共融资中，共筹得超过2亿3500万美元，包括首次公开募股。从1989年到1992年，他是位于加州阿拉米达的Somatix Therapy Corp.研发部门的副总裁，同时从1985年到1989年是位于加州阿拉米达的Triton Biosciences Inc.所属分子和细胞生物部门的董事。此前，从1982年到1985年，他是位于新泽西州纳特利的Hoffmann-LaRoche, Inc.分子遗传部门的研究团队主管，同时从1975年到1977年，他是特州休斯敦市贝勒医学院（Baylor College of Medicine）讲师。他在1974年从加拿大的麦克马斯特大学（McMaster University）获得生物化学博士学位，在1969年从爱尔兰都柏林大学（University College Dublin）获得学士学位。Monahan先生是加州Tacere Therapeutics董事会成员。他还是一些爱尔兰生物技术公司的董事会成员，包括Genable、Cellix、Luxcel、Identigen、Pharmatrin以及GK Technologies。
- John Monahan has been a member of the Company’s Board of Directors since November 11 2020. Dr. Monahan has served on the board of directors of Heat Biologics, Inc. Nasdaq: HTBX, a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines since November 2009 and from August 2016 until May 2021 also served on the board of directors of the biotech company Anixa Biosciences, Inc. (formerly known as ITUS Corporation)(Nasdaq: ANIX), a biotechnology company focused on using the body’s immune system to diagnose, treat and prevent cancer. He is also a board member of Cellix Ltd. (Ireland) and has served on a number of other public and private boards over the years. Dr. Monahan Co-Founded Avigen Inc. (Nasdaq: AVGN) in 1992 a company which has become a leader in its sector for the development of novel pharmaceutical products for the treatment of serious human diseases. Over a 12 year period as Chief Executive Officer of Avigen he raised over $235 million in several private and public financings including its initial public offering. From 1989-1992 he was Vice President of Research & Development at Somatix Therapy Corp., Alameda, CA and from 1985-1989 he was Director of Molecular & Cell Biology at Triton Biosciences Inc., Alameda, CA. Prior to that from 1982-1985 he was Research Group Chief, Department of Molecular Genetics, Hoffmann-LaRoche, Inc. Nutley, NJ, and from 1975 to 1977 he was an Instructor at Baylor College of Medicine, Houston TX. Dr. Monahan served as a scientific advisory consultant to the Company from 2015 to November 10 2020 and from 2010 through 2015 he was the Company’s Senior Executive Vice President of Research & Development. Dr. Monahan was also a Scientific Advisory Board member of Agilis Biotherapeutics (recently merged into PTC Therapeutics), from 2014 to 2019. Dr. Monahan received his Ph.D. in Biochemistry from McMaster University, Canada and his B.Sc. from University College Dublin, Ireland.
高管简历
中英对照 | 中文 | 英文- William L. Ostrander
WilliamL.Ostrander于2019年9月加入本公司，担任财务Vice President兼秘书。Ostrander先生在公共和私人公司拥有超过22年的财务管理经验。加入Heat Biologics之前，Ostrander先生担任Liquidia Technologies的财务执行董事，这是一家公开上市的生物制药公司。此前，他曾担任KBI Biopharma公司（生物制药合同服务公司）的高级财务和会计董事。他也曾担任LexisNexis Risk Solutions公司（数据分析解决方案公司）的财务经理。此前，他曾担任Seisint公司（私人信息产品公司，被LexisNexis公司收购）的总会计师。他也曾担任Boca Research公司（数据通信硬件制造商）的高级财务经理，也曾担任其他会计和财务职务。Ostrander先生拥有中央密歇根大学（Central Michigan University）的金融学学士学位。
William L. Ostrander currently serves as our Chief Financial Officer, a position he was appointed to on January 4 2021 and has served as our Secretary since September 25 2019 when he joined our company as Vice President of Finance. Mr. Ostrander has over 22 years of experience in financial management at public and private companies. From November 2014 until joining our company, Mr. Ostrander served as Executive Director of Finance at Liquidia Technologies, Corporation, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint, Inc., a private information products company that was acquired by LexisNexis. He also served as Senior Manager, Finance and held other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Mr. Ostrander holds a B.S. in Finance from Central Michigan University.- WilliamL.Ostrander于2019年9月加入本公司，担任财务Vice President兼秘书。Ostrander先生在公共和私人公司拥有超过22年的财务管理经验。加入Heat Biologics之前，Ostrander先生担任Liquidia Technologies的财务执行董事，这是一家公开上市的生物制药公司。此前，他曾担任KBI Biopharma公司（生物制药合同服务公司）的高级财务和会计董事。他也曾担任LexisNexis Risk Solutions公司（数据分析解决方案公司）的财务经理。此前，他曾担任Seisint公司（私人信息产品公司，被LexisNexis公司收购）的总会计师。他也曾担任Boca Research公司（数据通信硬件制造商）的高级财务经理，也曾担任其他会计和财务职务。Ostrander先生拥有中央密歇根大学（Central Michigan University）的金融学学士学位。
- William L. Ostrander currently serves as our Chief Financial Officer, a position he was appointed to on January 4 2021 and has served as our Secretary since September 25 2019 when he joined our company as Vice President of Finance. Mr. Ostrander has over 22 years of experience in financial management at public and private companies. From November 2014 until joining our company, Mr. Ostrander served as Executive Director of Finance at Liquidia Technologies, Corporation, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint, Inc., a private information products company that was acquired by LexisNexis. He also served as Senior Manager, Finance and held other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Mr. Ostrander holds a B.S. in Finance from Central Michigan University.
- Jeffrey Wolf
Jeffrey Wolf，一名法学博士，自2006年以来成为董事，在基于研究和技术进行创建、融资、培育和发展新企业方面拥有大量经验。在2008年8月，他创立Heat Biologics, Inc.（纳斯达克交易代码：HTBX），这是一家上市公司，从事对抗癌症和其他疾病的药物研究与开发。自2010年4月以来，他担任Heat Biologics, Inc.的首席执行官和董事会主席。在成立Heat Biologics, Inc.之前，从1997年6月至2011年3月，他担任Seed-One Ventures, LLC的常务董事，这是一家风险投资公司，专注于刚成立的特殊医疗公司的创设和成长。自Seed-One成立以来，他创办并运行一些医疗公司。他新创的企业包括Avigen（一家位于旧金山的基因治疗公司），他担任其联合创始人和董事；TyRx Pharma（一家位于普林斯顿的公司，专注于生物相容性聚合物的发展），他担任其联合创始人兼董事长；EluSys Therapeutics（一家位于新泽西（New Jersey）的公司，专注于将血源性病原体移除的新技术的发展），他担任其联合创始人、董事长兼首席执行官；以及GenerationOne（一家位于迈阿密（Miami）的公司，专注于移动协同式医疗（mobile-based collaborative care）），他担任其创始人、董事长兼首席执行官。他从斯坦福商学院（Stanford Business School）获得M.B.A。学位；从纽约大学法学院（New York University School of Law）获得法学博士学位；从芝加哥大学（University of Chicago）获得学士学位，在那里他以优异的成绩从经济学专业毕业。他是几个Seed-One投资组合公司的董事。
Jeffrey Wolf,who has been a member of the Company’s Board of Directors since 2006 has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In August 2008 Mr. Wolf founded Heat Biologics, Inc. NASDAQ: HTBX, a publicly traded company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010 Mr. Wolf has served as the Chief Executive Officer and Chairman of the Board of Heat Biologics, Inc. Prior to founding Heat Biologics, Inc., from June 1997 to March 2011 Mr. Wolf has served as managing director at Seed-One Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding Seed-One, Mr. Wolf has founded and run several medical companies. Mr. Wolf’s start-ups include Avigen, a San Francisco-based gene therapy company where he was a co-founder and director; TyRx Pharma, a Princeton-based company focused on the development of bio-compatible polymers where he was a co-founder and Chairman; EluSys Therapeutics, a New Jersey company focused on the development of novel technology to remove blood-borne pathogens where he was a cofounder, Chairman and Chief Executive Officer; and GenerationOne, a Miami-based company focused on mobile-based collaborative care, where he was the founder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as a director of several Seed-One portfolio companies.- Jeffrey Wolf，一名法学博士，自2006年以来成为董事，在基于研究和技术进行创建、融资、培育和发展新企业方面拥有大量经验。在2008年8月，他创立Heat Biologics, Inc.（纳斯达克交易代码：HTBX），这是一家上市公司，从事对抗癌症和其他疾病的药物研究与开发。自2010年4月以来，他担任Heat Biologics, Inc.的首席执行官和董事会主席。在成立Heat Biologics, Inc.之前，从1997年6月至2011年3月，他担任Seed-One Ventures, LLC的常务董事，这是一家风险投资公司，专注于刚成立的特殊医疗公司的创设和成长。自Seed-One成立以来，他创办并运行一些医疗公司。他新创的企业包括Avigen（一家位于旧金山的基因治疗公司），他担任其联合创始人和董事；TyRx Pharma（一家位于普林斯顿的公司，专注于生物相容性聚合物的发展），他担任其联合创始人兼董事长；EluSys Therapeutics（一家位于新泽西（New Jersey）的公司，专注于将血源性病原体移除的新技术的发展），他担任其联合创始人、董事长兼首席执行官；以及GenerationOne（一家位于迈阿密（Miami）的公司，专注于移动协同式医疗（mobile-based collaborative care）），他担任其创始人、董事长兼首席执行官。他从斯坦福商学院（Stanford Business School）获得M.B.A。学位；从纽约大学法学院（New York University School of Law）获得法学博士学位；从芝加哥大学（University of Chicago）获得学士学位，在那里他以优异的成绩从经济学专业毕业。他是几个Seed-One投资组合公司的董事。
- Jeffrey Wolf,who has been a member of the Company’s Board of Directors since 2006 has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In August 2008 Mr. Wolf founded Heat Biologics, Inc. NASDAQ: HTBX, a publicly traded company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010 Mr. Wolf has served as the Chief Executive Officer and Chairman of the Board of Heat Biologics, Inc. Prior to founding Heat Biologics, Inc., from June 1997 to March 2011 Mr. Wolf has served as managing director at Seed-One Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding Seed-One, Mr. Wolf has founded and run several medical companies. Mr. Wolf’s start-ups include Avigen, a San Francisco-based gene therapy company where he was a co-founder and director; TyRx Pharma, a Princeton-based company focused on the development of bio-compatible polymers where he was a co-founder and Chairman; EluSys Therapeutics, a New Jersey company focused on the development of novel technology to remove blood-borne pathogens where he was a cofounder, Chairman and Chief Executive Officer; and GenerationOne, a Miami-based company focused on mobile-based collaborative care, where he was the founder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as a director of several Seed-One portfolio companies.